RxDoctor Payments DataLook up a doctor →

Charlecinth Roberts, MD

Family Medicine · Hartford, CTNPI 1700105624

Payments from drug & device makers

$7,815in general payments, 2019–2025

Across 396 payments — averaging $19.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$714
  • Pfizer$663
  • AbbVie$621
  • AstraZeneca$607
  • GSK$420
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,810100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,815 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$39,667
Medicare patients
66
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide163$223,776
MounjaroTirzepatide57$66,522
JardianceEmpagliflozin49$53,372
JanuviaSitagliptin Phosphate31$46,441
FarxigaDapagliflozin Propanediol35$36,622
EliquisApixaban41$32,208
LinzessLinaclotide43$28,645
EntrestoSacubitril/Valsartan31$24,285
Soliqua 100-33Insulin Glargine/Lixisenatide22$22,123
XareltoRivaroxaban15$21,957
Tresiba Flextouch U-100Insulin Degludec18$21,440
Rufinamide13$21,421
Tresiba Flextouch U-200Insulin Degludec18$16,674
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$14,807
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,703$223,776163 claims
Lilly USA, LLCMounjaro$714$66,52257 claims
MerckJanuvia$164$46,44131 claims
AstraZenecaFarxiga, Bevespi Aerosphere$607$41,83947 claims
PfizerEliquis$663$32,20841 claims
AbbVieLinzess$621$28,64543 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$420$26,13449 claims
NovartisEntresto$16$24,28531 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$236$22,12322 claims
Johnson & JohnsonXarelto$47$21,95715 claims
Astellas Pharma US IncMyrbetriq$262$5,90913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →